Navigation Links
Treatment for fibroids with "Abortion Pill"

Women suffering form fibroids, who until now had only an option of a hysterectomy or removal of the fibroid, now have an alternative of shrinking the fibroid with the drug Mifepristone. Lead researcher Steven H. Eisinger, MD, said that fibroids are a common and vexing problem in women and fibroid relief accounts for about 30% of all hysterectomies in the U.S. Women who are symptomatic could have back pain, pain with intercourse, problems with bowels and bladder, and most especially heavy bleeding. Many of these women are also chronically// anemic.

Mifepristone was approved by the FDA in 2000 after a lot of controversies and since then studies have shown that the drug could be a possible contraceptive, a treatment for endometriosis, and a possible remedy for fibroids. Eisinger conducted a study with 20 women who all had large fibroids and multiple symptoms -- including heavy periods, pelvic pain and pressure, and lower back pain. The women were randomly asked to take either 5 mg or 10 mg of Mifepristone daily -- the very lowest doses. At the end of the study all women had a remarkable shrinkage of the fibroid, by about one-half. They also showed significant symptom relief.

An interesting fact about Mifepristone is that it stops monthly menstruation completely, giving many of these women with fibroids, who are chronically anemic, a chance to raise their blood count. They feel much better, healthier, and if they need surgery, they are much more likely to not require blood transfusion. Eisinger added that Mifepristone, compared to the currently available drug for fibroid-shrinking - Lupron (leuprolide acetate), would be cheaper and better tolerated and would work just as well. Lupron, used as a preoperative treatment to assist in the surgical removal of fibroids, decreases the body's production of estrogen to menopausal levels. Though this is useful in shrinking fibroids, side effects such as hot flashes and vaginal dryness can come with the estrog en decrease. Also Mifepristone has been shown in Eisinger's study as effective in all women, while it cannot be said so with Lupron. However, Elizabeth Ginsburg, MD, an Obstetrics/Gynecology and Fertility specialist at Brigham & Women's Hospital in Boston cautioned that there may be long-term safety issues connected with Mifepristone as almost a third of the women in Eisinger's study had developed hyperplasia of the lining of the uterus. Though, it is not a cancerous lesion, hyperplasia can become cancerous over many years' time.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the ... series, and attorneys from the firm’s global Life Sciences & Medical Technology Group have ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... as possible. With this in mind, SIGVARIS has created a new line of ... during bed rest and provide the benefits of graduated compression when transitioning from ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Valeant Pharmaceuticals International, Inc. (NYSE: ... positive results from a Phase 3, multicenter double-blind, ... and efficacy of IDP-118 (halobetasol propionate and tazarotene) ... Within the Phase 3 study of ... IDP-118 showed statistical significance to vehicle with a ...
(Date:12/8/2016)... Information products and services provider Elsevier has launched ... largest abstract and citation database of peer-reviewed literature, providing the scholarly ... publishers. The new set of metrics will improve decisions on where ... a journal,s editorial strategy. ... , CiteScore metrics comprise a ...
(Date:12/8/2016)... 2016 Dignitana, a world leader in medical ... Technology, creator of the award-winning, patented Boa® system, to ... the DigniCap® scalp cooling system. DigniCap® was cleared by ... and is the first medical scalp cooling device to ... system features a patented tight-fitting silicone cooling cap that ...
Breaking Medicine Technology: